API
< Back to situation

[REVISION HISTORY]

Brazil clinical research regulatory and sectoral development

2 recorded revisions of this situation.

What changed

2026-11-11 21:06 UTC → 2026-11-20 01:59 UTC · added removed

Brazil has seen an increase in global clinical research participation following the implementation of Law 14.874, the Clinical Research Law. Sanctioned in May 2024 and regulated in October 2025, this legislation established the first dedicated legal framework for the sector, creating the National System of Ethics in Research Involving Humans and shortening analysis timelines for ethical opinions. Following these regulatory changes, To support this framework, the Brazilian Ministry of Health launched an initiative to establish the National Registry of Clinical Research Centers (CNCPC). Supported Coordinated by an investment the Clinical Research Unit of the Botucatu Medical School at Unesp, the project is supported by R$ 4.5 million from the Ministry of Health and CNPq, the CNPq. The registry aims to create a standardized database map the infrastructure, specialized teams, and expertise of public and private research centers, including hospitals, universities, and clinics. The project seeks diagnostic laboratories. Fernanda De Negri, secretary of the Secretariat of Science, Technology, and Innovation in Health (SCTIE), stated the mapping is intended to identify scientific potential, increase transparency, and reduce regional inequalities to better align research with the needs of the Unified Health System (SUS). A recent census conducted by Sindusfarma in partnership with and Datafolha indicates that shows oncology is the primary focus of pharmaceutical clinical studies in Brazil, accounting for 17.8% of researched areas. Other significant areas include Brazil at 17.8%, followed by metabolic and endocrine diseases (15%), autoimmune and inflammatory diseases (14.9%), and the central nervous system (13.7%). Looking ahead, 65% of companies intend to increase research investments over the next five years. Oncology remains investments, with oncology remaining the top priority for 26% of these firms, followed by firms. In Brasília, the central nervous system (25%) Ministry of Health recently hosted international forums focused on strengthening clinical research, genomic knowledge, and rare diseases (22%). This focus is critical as precision public health. Strategic initiatives discussed include the regulation of human research, the creation of the National Cancer Institute (Inca) estimates 781,000 new cancer cases annually Ethics in Brazil between 2026 Research Instance (Inaep), and 2028. the development of a national genomic database.

Versions

  1. 2026-11-20 01:59 UTC Brazil clinical research regulatory and sectoral development
  2. 2026-11-11 21:06 UTC Brazil clinical research regulatory and sectoral development
  3. 2026-11-05 23:16 UTC Brazil clinical research regulatory development

Select a version to see what changed compared to the one before it.